Biochemistry of Statins

Advances in Clinical Chemistry

Volumn 73, Issue , 2016, Pages 127-168

  Egom, Emmanuel Eroume A ^a,b   Hafeez, Hafsa ^b  

^a TRINITY COLLEGE DUBLIN   (Ireland)

^b Egom Clinical and Translational Research Services   (Canada)

Author keywords

Cardiovascular disease; Low density lipoprotein cholesterol; Statins

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

BEHAVIOR; CHEMICAL STRUCTURE; CHEMICALLY INDUCED; CHEMISTRY; COGNITION; DIABETES MELLITUS; DRUG EFFECTS; DRUG INTERACTION; DYSLIPIDEMIAS; HUMAN; KIDNEY DISEASE; MUSCLE DISEASE; TOXIC HEPATITIS;

BEHAVIOR; COGNITION; DIABETES MELLITUS; DRUG INTERACTIONS; DRUG-INDUCED LIVER INJURY; DYSLIPIDEMIAS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KIDNEY DISEASES; MOLECULAR STRUCTURE; MUSCULAR DISEASES;

EID: 84954306698     PISSN: 00652423     EISSN: None     Source Type: Book Series    
DOI: 10.1016/bs.acc.2015.10.005     Document Type: Chapter

References (217)

1. Kapur N.K., Musunuru K. Clinical efficacy and safety of statins in managing cardiovascular risk. Vasc. Health Risk Manag. 2008, 4:341-353.
2. Tobert J.A. Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors. Nat. Rev. Drug Discov. 2003, 2:517-526.
3. Gofman J.W., Lindgren F.T., Elliott H. Ultracentrifugal studies of lipoproteins of human serum. J. Biol. Chem. 1949, 179:973-979.
4. Gofman J.W., Lindgren F. The role of lipids and lipoproteins in atherosclerosis. Science 1950, 111:166-171.
5. Gofman J.W. Serum lipoproteins and the evaluation of atherosclerosis. Ann. N. Y. Acad. Sci. 1956, 64:590-595.
6. Go A.S., Mozaffarian D., Roger V.L., Benjamin E.J., Berry J.D., Borden W.B., et al. Heart disease and stroke statistics-2013 update: a report from the American Heart Association. Circulation 2013, 127:e6-e245.
7. Stancu C., Sima A. Statins: mechanism of action and effects. J. Cell. Mol. Med. 2001, 5:378-387.
8. Gazzerro P., Proto M.C., Gangemi G., Malfitano A.M., Ciaglia E., Pisanti S., et al. Pharmacological actions of statins: a critical appraisal in the management of cancer. Pharmacol. Rev. 2012, 64:102-146.
9. Roche V.F. 'Teachers' topics: antihyperlipidemic statins: a self-contained, clinically relevant medicinal chemistry lesson. Am. J. Pharm. Educ. 2005, 69:546-560.
10. McTaggart F. Comparative pharmacology of rosuvastatin. Atheroscler. Suppl. 2003, 4:9-14.
11. Brunton L.L.C.B., Knollmann B.C. Drug Therapy for Hypercholesterolemia and Dyslipidemia 2011, McGraw-Hill, New York. twelfth ed.
12. White C.M. A review of the pharmacologic and pharmacokinetic aspects of rosuvastatin. J. Clin. Pharmacol. 2002, 42:963-970.
13. Pfefferkorn J.A., Song Y., Sun K.L., Miller S.R., Trivedi B.K., Choi C., et al. Design and synthesis of hepatoselective, pyrrole-based HMG-CoA reductase inhibitors. Bioorg. Med. Chem. Lett. 2007, 17:4538-4544.
14. Istvan E.S., Deisenhofer J. Structural mechanism for statin inhibition of HMG-CoA reductase. Science 2001, 292:1160-1164.
15. Corsini A., Maggi F.M., Catapano A.L. Pharmacology of competitive inhibitors of HMG-CoA reductase. Pharmacol. Res. 1995, 31:9-27.
16. N. Biljana, M. Ana, S. Miranda, A Review of Current Trends and Advances in Analytical Methods for Determination of Statins: Chromatography and Capillary Electrophoresis.
17. Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam. Clin. Pharmacol. 2005, 19:117-125.
18. Pan H.Y., DeVault A.R., Swites B.J., Whigan D., Ivashkiv E., Willard D.A., Brescia D. Pharmacokinetics and pharmacodynamics of pravastatin alone and with cholestyramine in hypercholesterolemia. Clin. Pharmacol. Ther. 1990, 48:201-207.
19. Cilla D.D., Gibson D.M., Whitfield L.R., Sedman A.J. Pharmacodynamic effects and pharmacokinetics of atorvastatin after administration to normocholesterolemic subjects in the morning and evening. J. Clin. Pharmacol. 1996, 36:604-609.
20. Garnett W.R. Interactions with hydroxymethylglutaryl-coenzyme A reductase inhibitors. Am. J. Health Syst. Pharm. 1995, 52:1639-1645.
21. Hamelin B.A., Turgeon J. Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors. Trends Pharmacol. Sci. 1998, 19:26-37.
22. Nezasa K., Higaki K., Takeuchi M., Nakano M., Koike M. Uptake of rosuvastatin by isolated rat hepatocytes: comparison with pravastatin. Xenobiotica 2003, 33:379-388.
23. Garcia M.J., Reinoso R.F., Sanchez Navarro A., Prous J.R. Clinical pharmacokinetics of statins. Methods Find. Exp. Clin. Pharmacol. 2003, 25:457-481.
24. Whirl-Carrillo M., McDonagh E.M., Hebert J.M., Gong L., Sangkuhl K., Thorn C.F., et al. Pharmacogenomics knowledge for personalized medicine. Clin. Pharmacol. Ther. 2012, 92:414-417.
25. Duggan D.E., Vickers S. Physiological disposition of HMG-CoA-reductase inhibitors. Drug Metab. Rev. 1990, 22:333-362.
26. Bottorff M., Hansten P. Long-term safety of hepatic hydroxymethyl glutaryl coenzyme A reductase inhibitors: the role of metabolism-monograph for physicians. Arch. Intern. Med. 2000, 160:2273-2280.
27. Corsini A., Bellosta S., Baetta R., Fumagalli R., Paoletti R., Bernini F. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol. Ther. 1999, 84:413-428.
28. Lennernas H., Fager G. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences. Clin. Pharmacokinet. 1997, 32:403-425.
29. Kitamura S., Maeda K., Wang Y., Sugiyama Y. Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin. Drug Metab. Dispos. 2008, 36:2014-2023.
30. Hatanaka T. Clinical pharmacokinetics of pravastatin: mechanisms of pharmacokinetic events. Clin. Pharmacokinet. 2000, 39:397-412.
31. Gazzerro P., Bifulco M. Statins and cancer in gastroenterology: new insight?. Gastroenterology 2013, 144:1572-1573.
32. Endo A., Kuroda M., Tanzawa K. Competitive inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase by ML-236A and ML-236B fungal metabolites, having hypocholesterolemic activity. FEBS Lett. 1976, 72:323-326.
33. Bischoff K.M., Rodwell V.W. Biosynthesis and characterization of (S)-and (R)-3-hydroxy-3-methylglutaryl coenzyme A. Biochem. Med. Metab. Biol. 1992, 48:149-158.
34. Brown M.S., Goldstein J.L. A receptor-mediated pathway for cholesterol homeostasis. Science 1986, 232:34-47.
35. Sehayek E., Butbul E., Avner R., Levkovitz H., Eisenberg S. Enhanced cellular metabolism of very low density lipoprotein by simvastatin. A novel mechanism of action of HMG-CoA reductase inhibitors. Eur. J. Clin. Invest. 1994, 24:173-178.
36. Chow S.C. Immunomodulation by statins: mechanisms and potential impact on autoimmune diseases. Arch. Immunol. Ther. Exp. (Warsz.) 2009, 57:243-251.
37. Zhou Q., Liao J.K. Pleiotropic effects of statins-basic research and clinical perspectives. Circ. J. 2010, 74:818-826.
38. Egom E.E., Rose R.A., Neyses L., Soran H., Cleland J.G., Mamas M.A. Activation of sphingosine-1-phosphate signalling as a potential underlying mechanism of the pleiotropic effects of statin therapy. Crit. Rev. Clin. Lab. Sci. 2013, 50:79-89.
39. Miettinen T.A. Diurnal variation of cholesterol precursors squalene and methyl sterols in human plasma lipoproteins. J. Lipid Res. 1982, 23:466-473.
40. Black D.M. A general assessment of the safety of HMG CoA reductase inhibitors (statins). Curr. Atheroscler. Rep. 2002, 4:34-41.
41. Keating A.J., Campbell K.B., Guyton J.R. Intermittent nondaily dosing strategies in patients with previous statin-induced myopathy. Ann. Pharmacother. 2013, 47:398-404.
42. Rindone J.P., Hiller D., Arriola G. A comparison of fluvastatin 40 mg every other day versus 20 mg every day in patients with hypercholesterolemia. Pharmacotherapy 1998, 18:836-839.
43. Matalka M.S., Ravnan M.C., Deedwania P.C. Is alternate daily dose of atorvastatin effective in treating patients with hyperlipidemia? The Alternate Day Versus Daily Dosing of Atorvastatin Study (ADDAS). Am. Heart J. 2002, 144:674-677.
44. Jafari M., Ebrahimi R., Ahmadi-Kashani M., Balian H., Bashir M. Efficacy of alternate-day dosing versus daily dosing of atorvastatin. J. Cardiovasc. Pharmacol. Ther. 2003, 8:123-126.
45. Ferrer-Garcia J.C., Perez-Silvestre J., Martinez-Mir I., Herrera-Ballester A. Alternate-day dosing of atorvastatin: effects in treating type 2 diabetic patients with dyslipidaemia. Acta Diabetol. 2006, 43:75-78.
46. Wongwiwatthananukit S., Sansanayudh N., Dhummauppakorn R., Kitiyadisai C. Efficacy and safety of rosuvastatin every other day compared with once daily in patients with hypercholesterolemia. Ann. Pharmacother. 2006, 40:1917-1923.
47. Ruisinger J.F., Backes J.M., Gibson C.A., Moriarty P.M. Once-a-week rosuvastatin (2.5 to 20 mg) in patients with a previous statin intolerance. Am. J. Cardiol. 2009, 103:393-394.
48. Fugit R.V., Resch N.D. Conversion of patients from simvastatin to lovastatin in an outpatient pharmacy clinic. Am. J. Health Syst. Pharm. 2000, 57:1703-1708.
49. Patel R.J., Gray D.R., Pierce R., Jafari M. Impact of therapeutic interchange from pravastatin to lovastatin in a Veterans Affairs Medical Center. Am. J. Manag. Care 1999, 5:465-474.
50. Kendrach M.G., Kelly-Freeman M. Approximate equivalent rosuvastatin doses for temporary statin interchange programs. Ann. Pharmacother. 2004, 38:1286-1292.
51. Jacobson T.A. Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors. Am. J. Cardiol. 2004, 94:1140-1146.
52. Williams D., Feely J. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clin. Pharmacokinet. 2002, 41:343-370.
53. Holtzman C.W., Wiggins B.S., Spinler S.A. Role of P-glycoprotein in statin drug interactions. Pharmacotherapy 2006, 26:1601-1607.
54. Gallant J.E. Johns Hopkins HIV Guide 2012 2012, Jones & Bartlett Publishers.
55. (accessed on February 19). http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm200635.htm.
56. Neuvonen P.J., Niemi M., Backman J.T. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin. Pharmacol. Ther. 2006, 80:565-581.
57. Product information for Livalo. Kowa Pharmaceuticals America IM, AL 36117. February 2012.
58. PL Detail-Document, OATP Fruit Juice Drug Interactions. Pharmacist's Letter/Prescriber's Letter. June 2011.
59. Larsen M.L., Illingworth D.R. Drug treatment of dyslipoproteinemia. Med. Clin. North Am. 1994, 78:225-245.
60. Illingworth D.R., Stein E.A., Mitchel Y.B., Dujovne C.A., Frost P.H., Knopp R.H., et al. Comparative effects of lovastatin and niacin in primary hypercholesterolemia. A prospective trial. Arch. Intern. Med. 1994, 154:1586-1595.
61. Jones P., Kafonek S., Laurora I., Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am. J. Cardiol. 1998, 81:582-587.
62. Rosenson R.S. Rosuvastatin: a new inhibitor of HMG-coA reductase for the treatment of dyslipidemia. Expert Rev. Cardiovasc. Ther. 2003, 1:495-505.
63. Jones P.H., Davidson M.H., Stein E.A., Bays H.E., McKenney J.M., Miller E., et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am. J. Cardiol. 2003, 92:152-160.
64. Brown A.S., Bakker-Arkema R.G., Yellen L., Henley R.W., Guthrie R., Campbell C.F., et al. Treating patients with documented atherosclerosis to National Cholesterol Education Program-recommended low-density-lipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin and simvastatin. J. Am. Coll. Cardiol. 1998, 32:665-672.
65. Sprecher D.L., Abrams J., Allen J.W., Keane W.F., Chrysant S.G., Ginsberg H., et al. Low-dose combined therapy with fluvastatin and cholestyramine in hyperlipidemic patients. Ann. Intern. Med. 1994, 120:537-543.
66. Brown G., Albers J.J., Fisher L.D., Schaefer S.M., Lin J.T., Kaplan C., et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N. Engl. J. Med. 1990, 323:1289-1298.
67. Di Angelantonio E., Sarwar N., Perry P., Kaptoge S., Ray K.K., Thompson A., et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009, 302:1993-2000.
68. Kastelein J.J., Isaacsohn J.L., Ose L., Hunninghake D.B., Frohlich J., Davidson M.H., et al. Comparison of effects of simvastatin versus atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I levels. Am. J. Cardiol. 2000, 86:221-223.
69. Rosenson R.S., Otvos J.D., Hsia J. Effects of rosuvastatin and atorvastatin on LDL and HDL particle concentrations in patients with metabolic syndrome: a randomized, double-blind, controlled study. Diabetes Care 2009, 32:1087-1091.
70. Davidson M., McKenney J., Stein E., Schrott H., Bakker-Arkema R., Fayyad R., Black D. Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Atorvastatin Study Group I. Am. J. Cardiol. 1997, 79:1475-1481.
71. Bakker-Arkema R.G., Davidson M.H., Goldstein R.J., Davignon J., Isaacsohn J.L., Weiss S.R., et al. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. JAMA 1996, 275:128-133.
72. Dart A., Jerums G., Nicholson G., d'Emden M., Hamilton-Craig I., Tallis G., et al. A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients with hypercholesterolemia. Am. J. Cardiol. 1997, 80:39-44.
73. R. Rosenson, Statins: Actions, Side Effects, and Administration. UpToDate, Topic 4564, Version 43.0.
74. Mulder A.B., van Lijf H.J., Bon M.A., van den Bergh F.A., Touw D.J., Neef C., Vermes I. Association of polymorphism in the cytochrome CYP2D6 and the efficacy and tolerability of simvastatin. Clin. Pharmacol. Ther. 2001, 70:546-551.
75. Chasman D.I., Posada D., Subrahmanyan L., Cook N.R., Stanton V.P., Ridker P.M. Pharmacogenetic study of statin therapy and cholesterol reduction. JAMA 2004, 291:2821-2827.
76. Liao J.K. Safety and efficacy of statins in Asians. Am. J. Cardiol. 2007, 99:410-414.
77. Crisby M., Nordin-Fredriksson G., Shah P.K., Yano J., Zhu J., Nilsson J. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation 2001, 103:926-933.
78. Williams J.K., Sukhova G.K., Herrington D.M., Libby P. Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys. J. Am. Coll. Cardiol. 1998, 31:684-691.
79. Corti R., Fayad Z.A., Fuster V., Worthley S.G., Helft G., Chesebro J., et al. Effects of lipid-lowering by simvastatin on human atherosclerotic lesions: a longitudinal study by high-resolution, noninvasive magnetic resonance imaging. Circulation 2001, 104:249-252.
80. Corti R., Fuster V., Fayad Z.A., Worthley S.G., Helft G., Smith D., et al. Lipid lowering by simvastatin induces regression of human atherosclerotic lesions: two years' follow-up by high-resolution noninvasive magnetic resonance imaging. Circulation 2002, 106:2884-2887.
81. Stamler J., Wentworth D., Neaton J.D. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 1986, 256:2823-2828.
82. Ballantyne C.M., Grundy S.M., Oberman A., Kreisberg R.A., Havel R.J., Frost P.H., Haffner S.M. Hyperlipidemia: diagnostic and therapeutic perspectives. J. Clin. Endocrinol. Metab. 2000, 85:2089-2112.
83. Shepherd J., Cobbe S.M., Ford I., Isles C.G., Lorimer A.R., MacFarlane P.W., et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N. Engl. J. Med. 1995, 333:1301-1307.
84. Downs J.R., Clearfield M., Weis S., Whitney E., Shapiro D.R., Beere P.A., et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998, 279:1615-1622.
85. Sever P.S., Dahlof B., Poulter N.R., Wedel H., Beevers G., Caulfield M., et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003, 361:1149-1158.
86. Ridker P.M., Danielson E., Fonseca F.A., Genest J., Gotto A.M., Kastelein J.J., et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Engl. J. Med. 2008, 359:2195-2207.
87. Ray K.K., Seshasai S.R., Erqou S., Sever P., Jukema J.W., Ford I., Sattar N. Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65,229 participants. Arch. Intern. Med. 2010, 170:1024-1031.
88. Mihaylova B., Emberson J., Blackwell L., Keech A., Simes J., Barnes E.H., et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012, 380:581-590.
89. Stone N.J., Robinson J.G., Lichtenstein A.H., Bairey Merz C.N., Blum C.B., Eckel R.H., et al. ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2013, 129:S1-S45.
90. Goff D.C., Lloyd-Jones D.M., Bennett G., Coady S., D'Agostino R.B., Gibbons R., et al. ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J. Am. Coll. Cardiol. 2013, 63:2935-2959.
91. Pencina M.J., Navar-Boggan A.M., Dagostino R.B., Williams K., Neely B., Sniderman A.D., Peterson E.D. Application of new cholesterol guidelines to a population-based sample. N. Engl. J. Med. 2014, 370:1422-1431.
92. Guallar E., Laine C. Controversy over clinical guidelines: listen to the evidence, not the noise. Ann. Intern. Med. 2014, 160:361-362.
93. Ridker P.M., Cook N.R. Statins: new American guidelines for prevention of cardiovascular disease. Lancet 2013, 382:1762-1765.
94. Psaty B.M., Weiss N.S. ACC/AHA guideline on the treatment of blood cholesterol: a fresh interpretation of old evidence. JAMA 2013, 311:461-462.
95. Krumholz H.M. The new cholesterol and blood pressure guidelines: perspective on the path forward. JAMA 2014, 311:1403-1405.
96. Robinson J.G. Accumulating evidence for statins in primary prevention. JAMA 2013, 310:2405-2406.
97. Greenland P., Lauer M.S. Cholesterol lowering in 2015: still answering questions about how and in whom. JAMA 2015, 314:127-128.
98. Pursnani A., Massaro J.M., D'Agostino R.B., O'Donnell C.J., Hoffmann U. Guideline-based statin eligibility, coronary artery calcification, and cardiovascular events. JAMA 2015, 314:134-141.
99. Deano R.C., Pandya A., Jones E.C., Borden W.B. A look at statin cost-effectiveness in view of the 2013 ACC/AHA cholesterol management guidelines. Curr. Atheroscler. Rep. 2014, 16:438.
100. Pandya A., Sy S., Cho S., Weinstein M.C., Gaziano T.A. Cost-effectiveness of 10-year risk thresholds for initiation of statin therapy for primary prevention of cardiovascular disease. JAMA 2015, 314:142-150.
101. Lardizabal J.A., Deedwania P.C. Benefits of statin therapy and compliance in high risk cardiovascular patients. Vasc. Health Risk Manag. 2010, 6:843-853.
102. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994, 344:1383-1389.
103. Sacks F.M., Pfeffer M.A., Moye L.A., Rouleau J.L., Rutherford J.D., Cole T.G., et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N. Engl. J. Med. 1996, 335:1001-1009.
104. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N. Engl. J. Med. 1998, 339:1349-1357.
105. Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002, 360:7-22.
106. Wilt T.J., Bloomfield H.E., MacDonald R., Nelson D., Rutks I., Ho M., et al. Effectiveness of statin therapy in adults with coronary heart disease. Arch. Intern. Med. 2004, 164:1427-1436.
107. Stone N.J., Robinson J.G., Lichtenstein A.H., Bairey Merz C.N., Blum C.B., Eckel R.H., et al. ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J. Am. Coll. Cardiol. 2013, 63:2889-2934.
108. Armitage J. The safety of statins in clinical practice. Lancet 2007, 370:1781-1790.
109. Grundy S.M. Can statins cause chronic low-grade myopathy?. Ann. Intern. Med. 2002, 137:617-618.
110. Jacobson T.A. Toward "pain-free" statin prescribing: clinical algorithm for diagnosis and management of myalgia. Mayo Clin. Proc. 2008, 83:687-700.
111. Joy T.R., Hegele R.A. Narrative review: statin-related myopathy. Ann. Intern. Med. 2009, 150:858-868.
112. Apostolopoulou M., Corsini A., Roden M. The role of mitochondria in statin-induced myopathy. Eur. J. Clin. Invest. 2015, 45:745-754.
113. Baker S.K. Molecular clues into the pathogenesis of statin-mediated muscle toxicity. Muscle Nerve 2005, 31:572-580.
114. Berthold H.K., Naini A., Di Mauro S., Hallikainen M., Gylling H., Krone W., Gouni-Berthold I. Effect of ezetimibe and/or simvastatin on coenzyme Q10 levels in plasma: a randomised trial. Drug Saf. 2006, 29:703-712.
115. Laaksonen R., Jokelainen K., Sahi T., Tikkanen M.J., Himberg J.J. Decreases in serum ubiquinone concentrations do not result in reduced levels in muscle tissue during short-term simvastatin treatment in humans. Clin. Pharmacol. Ther. 1995, 57:62-66.
116. Ghirlanda G., Oradei A., Manto A., Lippa S., Uccioli L., Caputo S., et al. Evidence of plasma CoQ10-lowering effect by HMG-CoA reductase inhibitors: a double-blind, placebo-controlled study. J. Clin. Pharmacol. 1993, 33:226-229.
117. Rundek T., Naini A., Sacco R., Coates K., DiMauro S. Atorvastatin decreases the coenzyme Q10 level in the blood of patients at risk for cardiovascular disease and stroke. Arch. Neurol. 2004, 61:889-892.
118. Paiva H., Thelen K.M., Van Coster R., Smet J., De Paepe B., Mattila K.M., et al. High-dose statins and skeletal muscle metabolism in humans: a randomized, controlled trial. Clin. Pharmacol. Ther. 2005, 78:60-68.
119. Bleske B.E., Willis R.A., Anthony M., Casselberry N., Datwani M., Uhley V.E., et al. The effect of pravastatin and atorvastatin on coenzyme Q10. Am. Heart J. 2001, 142:E2.
120. Laaksonen R., Jokelainen K., Laakso J., Sahi T., Harkonen M., Tikkanen M.J., Himberg J.J. The effect of simvastatin treatment on natural antioxidants in low-density lipoproteins and high-energy phosphates and ubiquinone in skeletal muscle. Am. J. Cardiol. 1996, 77:851-854.
121. Lamperti C., Naini A.B., Lucchini V., Prelle A., Bresolin N., Moggio M., et al. Muscle coenzyme Q10 level in statin-related myopathy. Arch. Neurol. 2005, 62:1709-1712.
122. (UK) NCGC Lipid Modification: Cardiovascular Risk Assessment and the Modification of Blood Lipids for the Primary and Secondary Prevention of Cardiovascular Disease 2014, National Clinical Guideline Centre, London.
123. Stroes E.S., Thompson P.D., Corsini A., Vladutiu G.D., Raal F.J., Ray K.K., et al. Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur. Heart J. 2015, 36:1012-1022.
124. Sugiyama S. HMG CoA reductase inhibitor accelerates aging effect on diaphragm mitochondrial respiratory function in rats. Biochem. Mol. Biol. Int. 1998, 46:923-931.
125. Mabuchi H., Higashikata T., Kawashiri M., Katsuda S., Mizuno M., Nohara A., et al. Reduction of serum ubiquinol-10 and ubiquinone-10 levels by atorvastatin in hypercholesterolemic patients. J. Atheroscler. Thromb. 2005, 12:111-119.
126. Thomas J.E., Lee N., Thompson P.D. Statins provoking MELAS syndrome. A case report. Eur. Neurol. 2007, 57:232-235.
127. Kaufmann P., Torok M., Zahno A., Waldhauser K.M., Brecht K., Krahenbuhl S. Toxicity of statins on rat skeletal muscle mitochondria. Cell. Mol. Life Sci. 2006, 63:2415-2425.
128. Kwak H.B., Thalacker-Mercer A., Anderson E.J., Lin C.T., Kane D.A., Lee N.S., et al. Simvastatin impairs ADP-stimulated respiration and increases mitochondrial oxidative stress in primary human skeletal myotubes. Free Radic. Biol. Med. 2012, 52:198-207.
129. Mullen P.J., Luscher B., Scharnagl H., Krahenbuhl S., Brecht K. Effect of simvastatin on cholesterol metabolism in C2C12 myotubes and HepG2 cells, and consequences for statin-induced myopathy. Biochem. Pharmacol. 2010, 79:1200-1209.
130. Nakahara K., Kuriyama M., Sonoda Y., Yoshidome H., Nakagawa H., Fujiyama J., et al. Myopathy induced by HMG-CoA reductase inhibitors in rabbits: a pathological, electrophysiological, and biochemical study. Toxicol. Appl. Pharmacol. 1998, 152:99-106.
131. Schaefer W.H., Lawrence J.W., Loughlin A.F., Stoffregen D.A., Mixson L.A., Dean D.C., et al. Evaluation of ubiquinone concentration and mitochondrial function relative to cerivastatin-induced skeletal myopathy in rats. Toxicol. Appl. Pharmacol. 2004, 194:10-23.
132. Obayashi H., Nezu Y., Yokota H., Kiyosawa N., Mori K., Maeda N., et al. Cerivastatin induces type-I fiber-, not type-II fiber-, predominant muscular toxicity in the young male F344 rats. J. Toxicol. Sci. 2011, 36:445-452.
133. Bouitbir J., Charles A.L., Echaniz-Laguna A., Kindo M., Daussin F., Auwerx J., et al. Opposite effects of statins on mitochondria of cardiac and skeletal muscles: a 'mitohormesis' mechanism involving reactive oxygen species and PGC-1. Eur. Heart J. 2012, 33:1397-1407.
134. De Pinieux G., Chariot P., Ammi-Said M., Louarn F., Lejonc J.L., Astier A., et al. Lipid-lowering drugs and mitochondrial function: effects of HMG-CoA reductase inhibitors on serum ubiquinone and blood lactate/pyruvate ratio. Br. J. Clin. Pharmacol. 1996, 42:333-337.
135. Phillips P.S., Haas R.H., Bannykh S., Hathaway S., Gray N.L., Kimura B.J., et al. Statin-associated myopathy with normal creatine kinase levels. Ann. Intern. Med. 2002, 137:581-585.
136. Stringer H.A., Sohi G.K., Maguire J.A., Cote H.C. Decreased skeletal muscle mitochondrial DNA in patients with statin-induced myopathy. J. Neurol. Sci. 2013, 325:142-147.
137. Phillips P.S., Ciaraldi T.P., Kim D.L., Verity M.A., Wolfson T., Henry R.R. Myotoxic reactions to lipid-lowering therapy are associated with altered oxidation of fatty acids. Endocrine 2009, 35:38-46.
138. Iacobazzi V., Convertini P., Infantino V., Scarcia P., Todisco S., Palmieri F. Statins, fibrates and retinoic acid upregulate mitochondrial acylcarnitine carrier gene expression. Biochem. Biophys. Res. Commun. 2009, 388:643-647.
139. 2+ signaling alteration in skeletal muscle. Biochem. Biophys. Res. Commun. 2005, 329:1067-1075.
140. Sacher J., Weigl L., Werner M., Szegedi C., Hohenegger M. Delineation of myotoxicity induced by 3-hydroxy-3-methylglutaryl CoA reductase inhibitors in human skeletal muscle cells. J. Pharmacol. Exp. Ther. 2005, 314:1032-1041.
141. Hanai J., Cao P., Tanksale P., Imamura S., Koshimizu E., Zhao J., et al. The muscle-specific ubiquitin ligase atrogin-1/MAFbx mediates statin-induced muscle toxicity. J. Clin. Invest. 2007, 117:3940-3951.
142. Mancini G.B., Baker S., Bergeron J., Fitchett D., Frohlich J., Genest J., et al. Diagnosis, prevention, and management of statin adverse effects and intolerance: proceedings of a Canadian Working Group Consensus Conference. Can. J. Cardiol. 2013, 27:635-662.
143. Giordano N., Senesi M., Mattii G., Battisti E., Villanova M., Gennari C. Polymyositis associated with simvastatin. Lancet 1997, 349:1600-1601.
144. Folzenlogen D. A case of atorvastatin combined toxic myopathy and inflammatory myositis. J. Clin. Rheumatol. 2001, 7:340-345.
145. Goldman J.A., Fishman A.B., Lee J.E., Johnson R.J. The role of cholesterol-lowering agents in drug-induced rhabdomyolysis and polymyositis. Arthritis Rheum. 1989, 32:358-359.
146. Khattak F.H., Morris I.M., Branford W.A. Simvastatin-associated dermatomyositis. Br. J. Rheumatol. 1994, 33:199.
147. Noel B., Cerottini J.P., Panizzon R.G. Atorvastatin-induced dermatomyositis. Am. J. Med. 2001, 110:670-671.
148. Schalke B.B., Schmidt B., Toyka K., Hartung H.P. Pravastatin-associated inflammatory myopathy. N. Engl. J. Med. 1992, 327:649-650.
149. Vasconcelos O.M., Campbell W.W. Dermatomyositis-like syndrome and HMG-CoA reductase inhibitor (statin) intake. Muscle Nerve 2004, 30:803-807.
150. Needham M., Fabian V., Knezevic W., Panegyres P., Zilko P., Mastaglia F.L. Progressive myopathy with up-regulation of MHC-I associated with statin therapy. Neuromuscul. Disord. 2007, 17:194-200.
151. Laaksonen R., Katajamaa M., Paiva H., Sysi-Aho M., Saarinen L., Junni P., et al. A systems biology strategy reveals biological pathways and plasma biomarker candidates for potentially toxic statin-induced changes in muscle. PLoS One 2006, 1:e97.
152. Mammen A.L., Chung T., Christopher-Stine L., Rosen P., Rosen A., Doering K.R., Casciola-Rosen L.A. Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy. Arthritis Rheum. 2011, 63:713-721.
153. Murlasits Z., Radak Z. The effects of statin medications on aerobic exercise capacity and training adaptations. Sports Med. 2014, 44:1519-1530.
154. Lim S., Despres J.P., Koh K.K. Prevention of atherosclerosis in overweight/obese patients-in need of novel multi-targeted approaches. Circ. J. 2011, 75:1019-1027.
155. Monda K.L., Ballantyne C.M., North K.E. Longitudinal impact of physical activity on lipid profiles in middle-aged adults: the Atherosclerosis Risk in Communities Study. J. Lipid Res. 2009, 50:1685-1691.
156. Chomistek A.K., Chiuve S.E., Jensen M.K., Cook N.R., Rimm E.B. Vigorous physical activity, mediating biomarkers, and risk of myocardial infarction. Med. Sci. Sports Exerc. 2011, 43:1884-1890.
157. Mascitelli L., Pezzetta F. Physical activity in statin-treated patients. Int. J. Cardiol. 2009, 134:136-137.
158. Cotter K.A., Lachman M.E. No strain, no gain: psychosocial predictors of physical activity across the adult lifespan. J. Phys. Act. Health 2010, 7:584-594.
159. Kokkinos P.F., Faselis C., Myers J., Panagiotakos D., Doumas M. Interactive effects of fitness and statin treatment on mortality risk in veterans with dyslipidaemia: a cohort study. Lancet 2013, 381:394-399.
160. Barter P.J., Brandrup-Wognsen G., Palmer M.K., Nicholls S.J. Effect of statins on HDL-C: a complex process unrelated to changes in LDL-C: analysis of the VOYAGER Database. J. Lipid Res. 2010, 51:1546-1553.
161. Mikus C.R., Boyle L.J., Borengasser S.J., Oberlin D.J., Naples S.P., Fletcher J., et al. Simvastatin impairs exercise training adaptations. J. Am. Coll. Cardiol. 2013, 62:709-714.
162. Muraki A., Miyashita K., Mitsuishi M., Tamaki M., Tanaka K., Itoh H. Coenzyme Q10 reverses mitochondrial dysfunction in atorvastatin-treated mice and increases exercise endurance. J. Appl. Physiol. 1985, 113:479-486.
163. Sinzinger H., O'Grady J. Professional athletes suffering from familial hypercholesterolaemia rarely tolerate statin treatment because of muscular problems. Br. J. Clin. Pharmacol. 2004, 57:525-528.
164. Law M., Rudnicka A.R. Statin safety: a systematic review. Am. J. Cardiol. 2006, 97:52C-60C.
165. Bjornsson E., Jacobsen E.I., Kalaitzakis E. Hepatotoxicity associated with statins: reports of idiosyncratic liver injury post-marketing. J. Hepatol. 2012, 56:374-380.
166. Russo M.W., Hoofnagle J.H., Gu J., Fontana R.J., Barnhart H., Kleiner D.E., et al. Spectrum of statin hepatotoxicity: experience of the drug-induced liver injury network. Hepatology 2014, 60:679-686.
167. Cohen D.E., Anania F.A., Chalasani N. An assessment of statin safety by hepatologists. Am. J. Cardiol. 2006, 97:77C-81C.
168. Calderon R.M., Cubeddu L.X., Goldberg R.B., Schiff E.R. Statins in the treatment of dyslipidemia in the presence of elevated liver aminotransferase levels: a therapeutic dilemma. Mayo Clin. Proc. 2010, 85:349-356.
169. Bays H. Statin safety: an overview and assessment of the data-2005. Am. J. Cardiol. 2006, 97:6C-26C.
170. Alsheikh-Ali A.A., Ambrose M.S., Kuvin J.T., Karas R.H. The safety of rosuvastatin as used in common clinical practice: a postmarketing analysis. Circulation 2005, 111:3051-3057.
171. Grundy S.M. The issue of statin safety: where do we stand?. Circulation 2005, 111:3016-3019.
172. Vidt D.G., Cressman M.D., Harris S., Pears J.S., Hutchinson H.G. Rosuvastatin-induced arrest in progression of renal disease. Cardiology 2004, 102:52-60.
173. Sidaway J.E., Davidson R.G., McTaggart F., Orton T.C., Scott R.C., Smith G.J., Brunskill N.J. Inhibitors of 3-hydroxy-3-methylglutaryl-CoA reductase reduce receptor-mediated endocytosis in opossum kidney cells. J. Am. Soc. Nephrol. 2004, 15:2258-2265.
174. Muldoon M.F., Manuck S.B., Matthews K.A. Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials. BMJ 1990, 301:309-314.
175. Smith G.D., Song F., Sheldon T.A. Cholesterol lowering and mortality: the importance of considering initial level of risk. BMJ 1993, 306:1367-1373.
176. Morgan R.E., Palinkas L.A., Barrett-Connor E.L., Wingard D.L. Plasma cholesterol and depressive symptoms in older men. Lancet 1993, 341:75-79.
177. Yang C.C., Jick S.S., Jick H. Lipid-lowering drugs and the risk of depression and suicidal behavior. Arch. Intern. Med. 2003, 163:1926-1932.
178. Golomb B.A., Kane T., Dimsdale J.E. Severe irritability associated with statin cholesterol-lowering drugs. QJM 2004, 97:229-235.
179. Evans M.A., Golomb B.A. Statin-associated adverse cognitive effects: survey results from 171 patients. Pharmacotherapy 2009, 29:800-811.
180. Richardson K., Schoen M., French B., Umscheid C.A., Mitchell M.D., Arnold S.E., et al. Statins and cognitive function: a systematic review. Ann. Intern. Med. 2013, 159:688-697.
181. Newman T.B., Hulley S.B. Carcinogenicity of lipid-lowering drugs. JAMA 1996, 275:55-60.
182. Friis S., Poulsen A.H., Johnsen S.P., McLaughlin J.K., Fryzek J.P., Dalton S.O., et al. Cancer risk among statin users: a population-based cohort study. Int. J. Cancer 2005, 114:643-647.
183. Graaf M.R., Beiderbeck A.B., Egberts A.C., Richel D.J., Guchelaar H.J. The risk of cancer in users of statins. J. Clin. Oncol. 2004, 22:2388-2394.
184. Karp I., Behlouli H., Lelorier J., Pilote L. Statins and cancer risk. Am. J. Med. 2008, 121:302-309.
185. Poynter J.N., Gruber S.B., Higgins P.D., Almog R., Bonner J.D., Rennert H.S., et al. Statins and the risk of colorectal cancer. N. Engl. J. Med. 2005, 352:2184-2192.
186. Kaye J.A., Jick H. Statin use and cancer risk in the General Practice Research Database. Br. J. Cancer 2004, 90:635-637.
187. Jacobs E.J., Rodriguez C., Brady K.A., Connell C.J., Thun M.J., Calle E.E. Cholesterol-lowering drugs and colorectal cancer incidence in a large United States cohort. J. Natl. Cancer Inst. 2006, 98:69-72.
188. Coogan P.F., Smith J., Rosenberg L. Statin use and risk of colorectal cancer. J. Natl. Cancer Inst. 2007, 99:32-40.
189. Eliassen A.H., Colditz G.A., Rosner B., Willett W.C., Hankinson S.E. Serum lipids, lipid-lowering drugs, and the risk of breast cancer. Arch. Intern. Med. 2005, 165:2264-2271.
190. Baigent C., Blackwell L., Emberson J., Holland L.E., Reith C., Bhala N., et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010, 376:1670-1681.
191. Dale K.M., Coleman C.I., Henyan N.N., Kluger J., White C.M. Statins and cancer risk: a meta-analysis. JAMA 2006, 295:74-80.
192. Browning D.R., Martin R.M. Statins and risk of cancer: a systematic review and metaanalysis. Int. J. Cancer 2007, 120:833-843.
193. Emberson J.R., Kearney P.M., Blackwell L., Newman C., Reith C., Bhala N., et al. Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy. PLoS One 2012, 7:e29849.
194. Strandberg T.E., Pyorala K., Cook T.J., Wilhelmsen L., Faergeman O., Thorgeirsson G., et al. Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S). Lancet 2004, 364:771-777.
195. Ford I., Murray H., Packard C.J., Shepherd J., Macfarlane P.W., Cobbe S.M. Long-term follow-up of the West of Scotland Coronary Prevention Study. N. Engl. J. Med. 2007, 357:1477-1486.
196. Bulbulia R., Bowman L., Wallendszus K., Parish S., Armitage J., Peto R., Collins R. Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20,536 high-risk individuals: a randomised controlled trial. Lancet 2011, 378:2013-2020.
197. Yamakawa T., Takano T., Tanaka S., Kadonosono K., Terauchi Y. Influence of pitavastatin on glucose tolerance in patients with type 2 diabetes mellitus. J. Atheroscler. Thromb. 2008, 15:269-275.
198. Yu Y., Ohmori K., Chen Y., Sato C., Kiyomoto H., Shinomiya K., et al. Effects of pravastatin on progression of glucose intolerance and cardiovascular remodeling in a type II diabetes model. J. Am. Coll. Cardiol. 2004, 44:904-913.
199. Wong V., Stavar L., Szeto L., Uffelman K., Wang C.H., Fantus I.G., Lewis G.F. Atorvastatin induces insulin sensitization in Zucker lean and fatty rats. Atherosclerosis 2006, 184:348-355.
200. Chen Y., Ohmori K., Mizukawa M., Yoshida J., Zeng Y., Zhang L., et al. Differential impact of atorvastatin vs pravastatin on progressive insulin resistance and left ventricular diastolic dysfunction in a rat model of type II diabetes. Circ. J. 2007, 71:144-152.
201. Mita T., Watada H., Nakayama S., Abe M., Ogihara T., Shimizu T., et al. Preferable effect of pravastatin compared to atorvastatin on beta cell function in Japanese early-state type 2 diabetes with hypercholesterolemia. Endocr. J. 2007, 54:441-447.
202. Sathyapalan T., Kilpatrick E.S., Coady A.M., Atkin S.L. The effect of atorvastatin in patients with polycystic ovary syndrome: a randomized double-blind placebo-controlled study. J. Clin. Endocrinol. Metab. 2009, 94:103-108.
203. Mansi I., Frei C.R., Wang C.P., Mortensen E.M. Statins and new-onset diabetes mellitus and diabetic complications: a retrospective cohort study of US healthy adults. J. Gen. Intern. Med. 2015, 1-12.
204. Wang K.L., Liu C.J., Chao T.F., Huang C.M., Wu C.H., Chen S.J., et al. Statins, risk of diabetes, and implications on outcomes in the general population. J. Am. Coll. Cardiol. 2012, 60:1231-1238.
205. Ridker P.M., Pradhan A., MacFadyen J.G., Libby P., Glynn R.J. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet 2012, 380:565-571.
206. Gerson R.J., MacDonald J.S., Alberts A.W., Chen J., Yudkovitz J.B., Greenspan M.D., et al. On the etiology of subcapsular lenticular opacities produced in dogs receiving HMG-CoA reductase inhibitors. Exp. Eye Res. 1990, 50:65-78.
207. Schlienger R.G., Haefeli W.E., Jick H., Meier C.R. Risk of cataract in patients treated with statins. Arch. Intern. Med. 2001, 161:2021-2026.
208. Smeeth L., Hubbard R., Fletcher A.E. Cataract and the use of statins: a case-control study. QJM 2003, 96:337-343.
209. Klein B.E., Klein R., Lee K.E., Grady L.M. Statin use and incident nuclear cataract. JAMA 2006, 295:2752-2758.
210. Harris M.L., Bron A.J., Brown N.A., Keech A.C., Wallendszus K.R., Armitage J.M., et al. Absence of effect of simvastatin on the progression of lens opacities in a randomised placebo controlled study. Oxford Cholesterol Study Group. Br. J. Ophthalmol. 1995, 79:996-1002.
211. Hippisley-Cox J., Coupland C. Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database. BMJ 2010, 340:c2197.
212. Leuschen J., Mortensen E.M., Frei C.R., Mansi E.A., Panday V., Mansi I. Association of statin use with cataracts: a propensity score-matched analysis. JAMA Ophthalmol. 2013, 131:1427-1434.
213. Dobs A.S., Schrott H., Davidson M.H., Bays H., Stein E.A., Kush D., et al. Effects of high-dose simvastatin on adrenal and gonadal steroidogenesis in men with hypercholesterolemia. Metabolism 2000, 49:1234-1238.
214. Davidson M.H., Stein E.A., Dujovne C.A., Hunninghake D.B., Weiss S.R., Knopp R.H., et al. The efficacy and six-week tolerability of simvastatin 80 and 160 mg/day. Am. J. Cardiol. 1997, 79:38-42.
215. Azzarito C., Boiardi L., Vergoni W., Zini M., Portioli I. Testicular function in hypercholesterolemic male patients during prolonged simvastatin treatment. Horm. Metab. Res. 1996, 28:193-198.
216. Santini S.A., Carrozza C., Lulli P., Zuppi C., CarloTonolo G., Musumeci S. Atorvastatin treatment does not affect gonadal and adrenal hormones in type 2 diabetes patients with mild to moderate hypercholesterolemia. J. Atheroscler. Thromb. 2003, 10:160-164.
217. Hosokawa A., Bar-Oz B., Ito S. Use of lipid-lowering agents (statins) during pregnancy. Can. Fam. Physician 2003, 49:747-749.